BHS Leucocytosis and Leucopenia Dr Caers

BHS Leucocytosis and Leucopenia Dr Caers

Leucocytoses & leucopenia Jo Caers Dept of Clinical Hematology [email protected] Bone marrow Blood Granulopoiesis Proliferation & 5 days maturation Storage 1 day Marginisation& Circulation 1 day Tissues 1-2 days Granulopoiesis Proliferation & 5 days maturation Storage 1 day Marginisation& Circulation 1 day Tissues 1-2 days Granulopoiesis Proliferation & 5 days maturation Storage 1 day Marginisation& Circulation 1 day Tissues 1-2 days Lymphocytes Monocytes NORMAL BLOOD CELL COUNT Hemoglobin 12.0 – 15.0 g/dl (F) 13.0 – 17.0 g/dl (M) Red Blood Cells 3.9 – 5.6 x 10 6/µl (F) 4.5 – 6.5 x 10 6/µl (M) Hematocrit 36 – 48% (F) 40 – 52% (M) Mean Corpuscular Volume 80 – 95µ³ Mean Hb Concentration 27 – 34 pg Conc corp mean Hb 30 – 35 g/dl Reticulocytes 0.5 – 20 % Leucocytes 4.0 – 10.0 x 10 3/µl ¨ Neutophils 1.8 – 7.5 Lymphocytes 1.5 – 3.5 Monocytes 0.2 – 0.8 Eosinophils 0.04 – 0.45 Basophils 0.01 – 0.1 Platelets 100 – 400 x 10 3/dl Hyperleucocytosis > 10.000 WBC/mm³ Normal Cells Abnormal cells or blastic cells Infections ? Neutrophilia (> 7.500/mm³) Acute Leukemias Lymphocytosis (> 4.500/mm³) Chronic Myelomonocytic Leukemias Chronic Lymhocytic leukemia Chronic Myeloid Leukemia Non Hodgkin Lymphoma Chronic Monocytosis (> 800/mm³) … Inflammations? Eosinophilia (> 400/mm³) Basophilia (> 100/mm³) Leukoerythroblastic reaction Cytopenia with immature RBCs (normoblasts) immature WBCs (agranular neutrophils, myelocytes, metamyelocytes ) Causes BM infiltration • Solid tumor or hematological malignancy • Myelofibrosis Strong BM stimulation • Infection, inflammation, hypoxia, trauma • Severe Hemolytic or megaloblastic anemia • Massive bleeding Leukemoid reaction Leucocytosis ( > 50.000) similar to CML Causes - Infection (TB…) - Stress or infection in newborns - Intensive care Laboratory abnormalities - WBC > 50,000/µL - Formula deviated: immature WBC → hyposegmented neutrophils → métamyelocytes, myelocytes, promyelocytes, Neutropenia Neutrophilcount Riskof infection 1.000-1.500 No significant increase in infection risk 0.500-1,000 Some increased risk in infection (can generally be treated as an outpatient) <0.500 Major increased infection risk (treat all fevers with broad spectrum IV antibiotics as an inpatient CASE 1: ♂ 26 years old BLOOD CELL COUNT Differential Counts (%) - Blasts 1.77 WBC (10 9/L) - Myélocytes 5.88 RBC(10 12 /L) - Métamyelocytes 16.8 Hb(g/dl) 44 Hct (%) - Non segmented 80.7 MCV (fl) 15 Neutrophils 28.4 CMH (pg) 74 Lymphocytes 34 CCMH (g/L) 11 Monocytes 9 MPV (fl) 0.0 Eosinophils 183 Platelets 0.0 Basophils Inherited - Benign familial or racial neutropenia (Africa) - Kostmann Syndrome - Chediak-Higashi - Shwachman-Diamond syndrome - Cyclic Neutropenia: cycles of 3-4 weeks Acquired - Infection * Sepsis * Viral (HIV, HC, CMV, influenza…) - Drug induced - Immune * Auto-immune (Ac anti-neutrophils) * Lupus * Felty = RA + neutropenia and splenomegaly * Chronic benign neutropenia - Hypersplénism - Idiopathic - Pancytopenia (AA, MF, MDS, hematological malignancies) Drug-induced • Definitions - Neutropenia < 2,000 / µL - Agranulocytosis < 500 / µL • Plusieurs mécanismes (1) Central : ↓ granulopoiesis : dose-response effect (2) Central : ineffective granulopoïesis : dose-response effect (3) Periphery: Ab-mediated destruction : no dose-response Central Peripheral • production • destruction • Toxic • Immunologic • Dose-response effect • No dose-response effect • Progressive • Abruptly • Recovery: 2-4 weeks • Recovery: 1-2 weeks eg : chemotherapy eg : phenylbutazone • Médicaments - Rituximab delayed - Azathioprime, MMF C - Metamizol / amidopyrine / noramidopyrine 1/100 P - Phenylbutazone 1/100 P - Phenothiazine C - Thyroid (propylthiouracil , carbimazol) 1/100 C - Anti-epileptics (phenobarbital, DPH, mysoline, carbamazepine) C - Sulfonamides (cotrimoxazole , salazopyrine, chlorpropamide, dapsone) C/P - Indomethacine, diclofenac - Levamizole 2/100 P - Ticlopidine 2/100 P - Deferiprone 5/100 P - Clozapine 1/100 P - Antibiotics β-lactams P - Spironolactone - Procainamide CASE 1: ♂ 26 years old • BM cytology: normal granulopoiesis (normal differentiation) and erythropoiesis • Ultrasound abdomen: nl • Nl iron and vitamin status • Anti-nuclear antibodies: 1/1280 anti-SSA • Anca – • Rheumatoid factor - CASE 2 : ♂ 42 years old Leukocytosis discovered during routine « check-up » Complaints of fatigue and flu-like syndrome Examination: mild splenomegaly CASE 2 : ♂ 42 years old BLOOD CELL COUNTS DIFFERENTIAL (%) - Blasts 39.86 + WBC (10 9/L) 1+ Myelocytes 5.13 RBC (10 12 /L) 2+ Métamyelocytes 15.0 Hb (g/dl) Non segmented 44.6 Hct (%) + 86.9 MCV (fl) 84 Neutrophils 29.3 CMH (pg) 2- Lymphocytes 33.8 CCMH(g/L) 2 Monocytes 13.3 MPV (fl) - Eosinophils 695 + Platelets 9+ Basophils Neutrophilia • Etiologie - Infection - Inflammation (trauma, infarctus, vasculitis, rheumatology) - Drugs G-CSF, GM-CSF ( production & liberation) Corticosteroides (demargination ) Adrenalin (demargination ) - Tabac - Anesthesia, surgery - Exercice - Cold, heat stroke, burns, seizures - Cancer - Chronic stimulation of the BM (bleeding, hemolysis, iTP) - Post-splenectomy - Myéloproliferative disorders - Idiopathic MYELOPROLIFERATIVE NEOPLASMS CML MF PV ET Hématocrit N ou ↑ ↓↓ ↑↑ N Leucocytes ↑↑ ↑ ou ↑↑ ↑↑ ou N N Platelets ↑↑ ou N N ou ↓ ↑ ou N ↑↑ Splénomégaly +++ +++ + + LAP ↓ N ↑↑ N Fibrosis N ou ↑↑ +++ N ou ↑↑ N ou ↑↑ Cytogénétics Phi + Jak2 Jak2 (95%) Jak2/CalR Median Survival 12 1 –5 ans 10 + ans 10 + ans Acute leukemia <20% ? 10% < 10% < 10% Basophilia • Causes - Myeloproliferative neoplasms – CML – PV – TE – MF – Basophilic leucemia • Hypersensitivity reactions IgE–mediated • Inflammatory diseases (RA, RCUH, Crohn) Viral infections • Hypothyroidism • Hyperlipidemai • Oestrogens • Hyperlipidemia CASE 3: ♀ 45 years old • Leucocytosis discovered during « check-up » for asthenia • past History : unremarkable • Physical exam : Slenomegaly 2 cm below costal margin, No hepatomegaly, no lymphnodes. CASE 3: ♀ 45 years old BLOOD CELL COUNT Differential Counts (%) 22 +++ WBC (10 9/L) - Blasts - Myélocytes 4.88 RBC(10 12 /L) - Métamyelocytes 14.8 Hb (g/dl) 44 Hct (%) - Non segmented 90 MCV (fl) 12.3 Neutrophils 30.3 CMH (pg) 85.9 + Lymphocytes 34 CCMH (g/L) 0.0 - Monocytes 9 MPV (fl) 0.9 Eosinophils 183 Platelets 0.9 Basophils Lymphocytosis > 4.500 Ly/mm³ Atypical lympocytes ? EBV serology monoclonality pos neg B monoclonality T monoclonality Infectious CMV (T8↑) CLL / HCL / NHL mononucleosis Hepas (T8↑) ATCL/LGL MM (Ig intraC) (T8↑, T4/T8↓) Toxoplasmosis T NHL HIV (T4↓) Sezary S. (T4↑) Lymphocytosis > 4.500 Ly/mm³ Atypical lympocytes Normal lympocytes No monoclonolity EBV serology monoclonality Viral Acute Brucellosis Mycoplasma B monoclonality T monoclonality Pertussis Chronic Tuberculosis Infectious CMV serology ATCL/LGL CLL / HCL / NHL mononucleosis (T8↑) T NHL Sarcoïdosis MM (Ig intraC) (T8↑, T4/T8↓) Hepas (T8↑) Sezary S. (T4↑) Wegener Toxoplasmosis Syphilis III HIV serology (T4↓) Thyreotoxicosis adrenal insufficiency Pereira I et al Atlas of Peripheral Blood, 2012. B-polyclonal Lymphocytosis related to heavy smoking • Young ladies • Binucleated Lymphocytes • Polyclonal lymphocytes population • Splenomégaly : +/- • ↑ polyclonal IgM • Association with HLA-DR7 • Benign Evolution Leukemia – Lymphoma 1996: 275-279 Phenotype of Peripheral Blood LYMPHOCYTES T = CD3: 60 - 85% CD4: 40 - 60% CD4/CD8: 1.5 - 3 CD8: 20 - 40% B = CD19: 5 - 15% κ/λ : 1.5 à 2 Values in our patient : • Phenotype : 45% of B- lymphocytes (IgM, λ) , CD5 - CD23 - FMC7 +, CD25 + • CRP : < 0.5 mg/dl , LDH : NL , Viral Serology : NL DIFFERENTIAL DIAGNOSIS OF B- LYMPHOCYTOSIS F Chronic Hairy cell LK Prolymphocytic Follicular Mantle Cell Splenic vilous lymphocytic LK LK Lymphoma Lymphomas lymphomas CLL HCL PLL F NHL MCL* SVL ↑↑ lympho ++ + +++ + + +++ Spleen +/- ++ ++ +/- +/- +++ CD19 + + ++ ++ ++ ++ ++ CD5 ++ - -/+ - ++ - CD23 + - - -/+ - - CD10 - - + - - CD11c +/- ++ - - - - FMC7 - - ++ + + + CD103/25 - + - - - -/+ Mature T-cell lymphoproliferative disorders Marker T-LGLL NK-LGLL T-PLL ATLL SS TdT* ----- CD2 + + + + + CD3 ++ - ++ ++ ++ CD4 - - +/- ++ ++ CD5 + + + + + CD7 -/+ - +++ - -/+ CD8 ++ - -/+ - - CD16 + + - - - CD25 - - -/+ ++ -- CD56 -/+ + - - - Other CD11b+ HTLV1+ CD16+ CD57+ T-LGLL, T-cell large granular lymphocyte leukemia; NK-LGLL, NK-cell large granular lymphocyte leukemia; T- PLL, T cell prolymphocytic leukemia; ATLL, adult T cell leukemia/lymphoma; SS, Serazy syndrome. *TdT : terminal deoxynucleotidyl transferase differentiates these cells from lymphoblasts of ALL CASE 4: ♂ 23 years old Back from a stay in China for professional reasons Complaints : Fatigue, NS, subT ° , Weight loss +/- 2kg, No pruritus , no diarrhea. Past history : unremarkable Treatment : none Alcohol / tabacco : moderate Phys Exam : 5 cm diameter left Sub-clavicular LN CASE 4: ♂ 23 years old Differential (%) BLOOD CELL COUNT - Blasts 19.6 + WBC (10 9/L) - Myelocytes 12 4.3 RBC (10 /L) - Métamyelocytes 12.8 Hb (g/dl) - Non segmented 37.7 Hct (%) + 88.5 MCV (fl) 66.2 Neutrophils 29.6 MCH(pg) 7.9 Lymphocytes 33.9 MCCH (g/L) 7.3 + Monocytes 6.6 MPV (fl) 18.3 + Eosinophils 473.000 + Platelets 0.6 Basophils Causes of Eosinophilia Mild > 500, Moderate >1500, high >5000/ul • Allergies (industrialised countries) – atopia – Drug (Il-2 treatment) • Parasitosis (especially in developing countries) • Neoplasia – Hematological – - clonal eosinophilia in myeloid pathologies – - Polyclonal paraneoplasic eosinophilia in lymphoid pathologies – Solid tumors (uterus, lung, colon) • Idiopathic (SHE, GI eosinophilia, Eos pneumonia, Eosinophilic

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    42 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us